MRI contrast developer Epix Pharmaceuticals said it believes it has resolved patient accrual issues that had slowed progress in its phase IIa clinical trial for its investigational fibrin-binding imaging agent, EP-2104R.
The Cambridge, MA-based firm said that patient accrual increased to 35 as of January 3, and it now expects to complete full enrollment of 48 patients in the first quarter of this year. The fibrin-binding imaging agent will be used to image clots, particularly in the carotid arteries, which has potentially important ramifications for physicians evaluating patients at risk of stroke, Epix said.
By AuntMinnie.com staff writers
January 4, 2006
Related Reading
Epix hires consulting firm for acquisition analysis, December 16, 2005
Epix to slash workforce next month, December 14, 2005
Epix hit with Vasovist setback, November 23, 2005
Schering, Epix score European approval for Vasovist, October 5, 2005
Webb steps down at Epix, September 15, 2005
Copyright © 2006 AuntMinnie.com
